Blocking the activity of an essential protein to treat T-cell acute lymphoblastic leukaemia
Dr Maarten Hoogenkamp will continue his work into blocking the EAAT1 protein, which is crucial for the growth of T-cell acute lymphoblastic leukaemia.
Finding kinder drugs in genetically matched cell models for childhood leukaemia
Professor Alex Thompson and his team at the University of Nottingham aim to learn more about leukaemia to support the development of kinder treatments.
Targeting metabolism in aggressive childhood blood cancers
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.
Investigating the role of SET in childhood acute myeloid leukaemia to develop new treatments
Dr Maria Teresa Esposito hopes to learn more about a gene called SET in leukaemia and will test the best medicines to fight it.
Finding the most beneficial dose of fludarabine to optimise CAR-T therapy
Dr Shelby Barnett and Dr Geoff Shenton will monitor crucial drug levels in patients' blood in order to improve CAR T therapy protocols.
Fighting circular DNA to prevent relapse in acute lymphoblastic leukaemia
Looking at whether medicines that prevent circular DNA replication can help prevent relapse.
Why do some leukaemia patients have long-term problems with learning and memory
Finding a way to identify patients at risk of brain related side effects from leukaemia treatment, and gathering data to inform future treatment options.
Designing a safer way to find and fight acute myeloid leukaemia cells in children
Investigating a protein found on leukaemia stem cells, the cells which cause relapse, and whether it could be a good drug target.
Developing ways to identify chemotherapy resistant B-cell acute lymphoblastic leukaemia cells
Developing a test that can measure the amount of chemotherapy-resistant leukaemia cells in patient's blood samples. This would provide the foundations for future research.